Beta Drugs share price today

Beta Drugs Ltd's share price was ₹1,769.60 at the close on 4 November 2026. It has been rising for 18 weeks. That is 5.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,052 and ₹2,551, and at that close it sat 48% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Beta Drugs Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 5 weeks running.

Over the last 9.1 years the share price moved +1,689% while the NIFTY 500 moved +144%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 1 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: indian funds and insurers (DIIs) raised their stake for 7 quarters in a row, number of shareholders up 219% in a year and highest quarterly profit in 8 quarters.

1. Indian funds and insurers (DIIs) raised their stake for 7 quarters in a row

   From 0.2% to 6.5% of the company by the September 2026 quarter.

2. Number of shareholders up 219% in a year

   10,145 shareholders in the September 2026 quarter, against 3,184 a year earlier.

3. Highest quarterly profit in 8 quarters

   Profit of ₹19 crore in the September 2026 quarter is the highest of the last 8 quarters.

For July to September 2026 (the quarter ended 30 September 2026), Beta Drugs reported revenue of ₹137 crore, up 33.0% from ₹103 crore a year earlier, and a profit of ₹19.0 crore, up 58.3% from ₹12.0 crore.

Beta Drugs results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Beta Drugs' management discussed these results on a call held on 22 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Beta Drugs closed at ₹1,769.60 on 4 November 2026, up 6.0% from ₹1,670.20 a year earlier (7 November 2025) and up 214.8% over five years. Its highest weekly close since October 2017 was ₹2,550.70 on 14 August 2026.

Beta Drugs share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

477 weekly closes from 13 October 2017 to 4 November 2026.

4 Nov 2026: Beta Drugs closed at ₹1,769.60, down 1.6% on the week and down 14.6% on the month. 22 Oct 2026: Beta Drugs held its results call for July to September 2026. Management guided: FY27 consolidated revenue at ₹535 crore-plus.

Earlier

• Results for July to September 2026: Revenue up 33.0% and profit up 58.3% on a year earlier.

Beta Drugs has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

No. Beta Drugs Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 22 October 2026, Beta Drugs' management guided: FY27 consolidated revenue at ₹535 crore-plus.

“We have been doing the CDMO business for the past 15 years. Whenever a partner has been associated with us, we have never lost that partner.”Nipun, on the call for July to September 2026

What management guided

• FY27 own-brand sales of ₹150 crore.
• FY27 CMO revenue of ₹180-190 crore.
• Exports: ₹90-100 crore in FY27; ₹300 crore over 3-4 years at around 30% yearly growth; 50 registrations expected this year and 872 over 2-3 years.
• Consolidated growth of 20-25% over 3-5 years with sustained operating margin of 23-24%.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 22 October 2026.

When Beta Drugs reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Branded sales absorb the volume shifted by debottlenecking and sustain growth now that both plants operate normally.

Beta Drugs is on one of our India lists: Pharma stocks.

Beta Drugs Ltd earned ₹19.0 Cr of net profit in the Sep 2026 quarter, +58.3% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹41.0 Cr. Over 10 years profit has grown 45.0% a year on average. That is 13.9% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹12.0 Cr.

For the full year, FY26 profit was ₹41.0 Cr (−2.4% on the year before).

Why profit moved: revenue changed +33.0% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +22.9% and revenue +14.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Beta Drugs Ltd reported ₹137 Cr of revenue in the Sep 2026 quarter, +33.0% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown 30.9% a year on average. The last full year, FY26, came in at ₹384 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹444 Cr.

FY26 revenue was ₹384 Cr, +6.1% on the year before.

Recent pace: the last four quarters grew +14.5% on average, against 30.9% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +15.3%, against −13.3% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +26.2%, against −16.5% a year (accelerating).

Beta Drugs Ltd's operating margin was 22.0% in the Sep 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 0.0% and 23.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +1.4 percentage points on the year while gross margin changed +3.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 87% of Beta Drugs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹37.0 Cr of operating cash against ₹41.0 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹53.0 Cr of spending on assets, free cash was −₹16.0 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Beta Drugs Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹384 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹102 Cr on assets over the last 3 years.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Averaged over those years that is 8.9% of FY26 revenue a year.

Spending on assets: ₹102 Cr over the last 3 years, against ₹40.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Beta Drugs Ltd's P/E is 37.9×, near the high end of its own history: higher than 70% of past readings. Its usual P/E (the middle reading) is 31.1×, over 7.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹48.26.

Why the multiple is where it is: over the past year earnings per share moved −2.6% while the price moved +6.0%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 5 years the price moved +25.8% a year; about +20.9% a year came from earnings growth and about +4.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 50% on reported income across 13 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Beta Drugs Ltd's business is turning around. Profit growth has swung from −40.0% at its low to +26.2%, improving for 3 quarters in a row, with ROCE falling at 19.0%. This is based on 12 quarters of 4 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.